Medicinal cannabis: is current use clinically justified?

Area of Science:

• Pharmacology
• Pain Management
• Public Health

Background:

• Medicinal cannabis (MC) is increasingly marketed as a natural treatment for chronic non-cancer pain (CNCP).
• Over one million Australians are prescribed MC monthly, with over 800 products available, yet only two are TGA-approved.
• This highlights a gap between perceived benefits and regulatory approval.

Purpose of the Study:

• To evaluate the evidence for the efficacy and safety of MC in treating CNCP.
• To inform healthcare professionals and patients about the limitations of current MC research.
• To address the discrepancy between industry promotion and scientific evidence.

Main Methods:

• Systematic review of existing literature on MC for CNCP.
• Analysis of evidence quality and consistency across multiple reviews.
• Examination of regulatory approvals and product availability in Australia.

Main Results:

• Evidence for MC efficacy in CNCP is inconsistent and of low quality, except for neuropathic pain.
• Specific patient phenotypes benefiting from MC are not reliably identified.
• Under-reported adverse effects include cognitive impairment, sedation, and psychosis, particularly in older adults.

Conclusions:

• Current evidence does not support widespread or first-line use of MC for CNCP.
• Healthcare professionals must counsel patients on the significant limitations in efficacy and safety data.
• Resisting industry pressure for increased MC access is crucial given the evidence gaps.